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Abstract: Children with phenylketonuria (PKU) follow a protein restricted diet with negligible
amounts of docosahexaenoic acid (DHA). Low DHA intakes might explain subtle neurological deficits
in PKU. We studied whether a DHA supply modified plasma DHA and neurological and intellectual
functioning in PKU. In a double-blind multicentric trial, 109 PKU patients were randomized to DHA
doses from 0 to 7 mg/kg&day for six months. Before and after supplementation, we determined
plasma fatty acid concentrations, latencies of visually evoked potentials, fine and gross motor
behavior, and IQ. Fatty acid desaturase genotypes were also determined. DHA supplementation
increased plasma glycerophospholipid DHA proportional to dose by 0.4% DHA per 1 mg intake/kg
bodyweight. Functional outcomes were not associated with DHA status before and after intervention
and remained unchanged by supplementation. Genotypes were associated with plasma arachidonic
acid levels and, if considered together with the levels of the precursor alpha-linolenic acid, also with
DHA. Functional outcomes and supplementation effects were not significantly associated with
genotype. DHA intakes up to 7 mg/kg did not improve neurological functions in PKU children.
Nervous tissues may be less prone to low DHA levels after infancy, or higher doses might be required
to impact neurological functions. In situations of minimal dietary DHA, endogenous synthesis of
DHA from alpha-linolenic acid could relevantly contribute to DHA status.
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1. Introduction
Children with classical phenylketonuria (PKU, OMIM 261600) diagnosed by newborn screening
who receive adequate dietary treatment from the neonatal age onwards generally reach the normal
range of neurological and cognitive functioning, even though some differences in performance when
compared to healthy siblings have been demonstrated [1,2]. The PKU diet is based on a strictly
limited intake of natural protein, supplemented with a phenylalanine (Phe) free amino acid mixture.
The PKU diet generally excludes protein rich animal foods, such as dairy products, meat, eggs, and fish,
which are natural sources of the long chain polyunsaturated fatty acids (LC-PUFA) [3]. Humans can
endogenously produce LC-PUFA from precursor essential fatty acids, but the rate of conversion is
limited and dietary intake is the key determinant of blood levels of the n-3 long-chain polyunsaturated
fatty acid docosahexaenoic acid (DHA). Children with PKU often have significantly lower blood levels
of DHA than healthy controls [4–7].
Many studies in infancy have demonstrated the importance of an adequate LC-PUFA status for
optimal neurological development, even though such effects have not been confirmed in all studies [8].
LC-PUFA seem most important for neurological functions early in life and in the elderly, while a
functional benefit of LC-PUFA for children has remained controversial [9,10]. Supplementation studies
have focused on DHA, which is found in high amounts in the brain and the eye, where DHA is
important for membrane function, interacts with PPARs, is associated with neurotransmitter levels,
and acts as a precursor for docosanoids [11,12]. The variable results observed from studies investigating
the effect of DHA supplementation in children on cognitive or neurological functioning may in part
be due to confounding baseline DHA intake and status, as well as genetic variation in the activity
of the fatty acid desaturases (FADS) and elongases involved in LC-PUFA synthesis [9]. The low
baseline levels in PKU children suggest that they might benefit more from DHA than healthy children.
In several studies, neurological and cognitive improvements have been observed after supplementing
children with PKU with n-3 LC-PUFA [13–15]. Visually evoked potential latencies have been improved
with fish oil supplementation or a blend of n-3 and n-6 LC-PUFA [14,15]. A common feature of these
studies is a high dose of DHA (≥10 mg/kg&day) and the application of mixtures of eicosapentaenoic
acid (EPA) and DHA. The question about the DHA dosage required to achieve a beneficial effect has
remained unanswered.
The very low LC-PUFA intake in non-supplemented patients with PKU provides the opportunity
to study the relationship between plasma levels of essential fatty acids and their desaturation
and elongation products in the almost complete absence of the influence of dietary LC-PUFA.
It has been established that different genetic variants of ∆6-desaturase and ∆5-desaturase influence
LC-PUFA levels, with up to 30% of the variance of blood arachidonic acid (ARA) explained by single
nucleotide polymorphisms (SNPs) in the FADS gene cluster that predict the activity of desaturating
enzymes [16,17]. In addition to SNPs in the FADS1/FADS2/FADS3 gene cluster on chromosome 11,
SNPs of genes encoding fatty acid elongases also influence LC-PUFA levels [17].
As the same enzymes catalyze the conversion of n-6 linoleic acid (LA) to ARA and of n-3
α-linolenic acid (ALA) to DHA, it may be expected that there is a similar importance of the FADS
genotype for the corresponding fatty acid levels. However, there is a much smaller influence of the
FADS genotypes on DHA than on ARA levels. An observational study explained only 6% of the
variation of red blood cell DHA content in pregnant women by the FADS genotype [18], while other
studies found no significant influence of FADS genotypes on DHA levels [19,20]. This agrees with the
well-known importance of the dietary intake of DHA and EPA for blood levels [21].
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We aimed to assess the effects of different dosages of DHA supply in PKU children on fatty acid
levels in blood lipids and on neurocognitive outcomes.
2. Materials and Methods
The study was conducted as a double blind randomized multicentric clinical trial with an
intervention period of six months. Randomization was stratified for each study center. Patients
with established PKU were enrolled in six major metabolic centers treating PKU children in Germany
(Heidelberg, Munich), Italy (Milan), the UK (Birmingham), Turkey (Istanbul), and Spain (Santander).
PKU patients attending the corresponding outpatient departments and considered eligible were
invited to participate. All parents consented in writing to participate after detailed verbal and written
information was given. The study was conducted in accordance with the Declaration of Helsinki,
and the protocol was approved by the local Ethics committees of all participating hospitals and was
registered with clinical trials.gov (NCT00909012).
2.1. Inclusion and Exclusion Criteria
Eligibility criteria included patients aged from 5 to 13 years, a diagnosis of classical PKU,
continuous treatment from the newborn period, good metabolic control demonstrated by dietary
adherence with a low Phe diet and at least two plasma Phe measurements with an average below
480 µmol/L during the six-month period prior to study enrollment, weight between the 3rd and 97th
percentile according to the WHO standard, and a natural protein tolerance of ≤12 g/day. Patients
with additional co-morbidities or who consumed n-3 LC-PUFA supplements (separately or added to
L-amino acid supplement) were excluded from participation.
2.2. Intervention
The dietary intervention consisted of the randomized allocation to one of five types of capsules
providing 0, 20, 43, 80, or 127 mg of DHA per capsule in the form of triacylglycerols. Capsules were
prepared by Nutricia (Liverpool, UK) by mixing appropriate amounts of high oleic sunflower oil
and algal oil. The algal oil contained only trace amounts of LC-PUFA other than DHA, with all
concentrations below 0.1% (Supplementary Table S1). With the LA percentage in the supplements
ranging from 3.5% to 5.8%, the additional LA intake via formula for all children was below 60 mg per
day. Subjects with a body weight below 35 kg consumed one capsule daily and participants weighing
35 or more kg consumed two capsules daily. The different DHA contents per capsule and the different
numbers of capsules per day aimed to achieve a daily DHA intake from 0 to 7 mg per kg body weight.
Allocation concealment was achieved by the addition of orange flavor to all capsules.
2.3. Outcome Assessments
Before the start of the capsule intervention, baseline examinations were performed and venous
blood was collected. As an indicator of neurological function, latencies of visually evoked potentials
(VEP) were recorded using a suitable device for recording pattern reversal, with a filter setting of 1 to
100 Hz, sensitivity of 20 µV/div, and time base of 30 ms/div. The patients were exposed to alternating
black and white checkerboard patterns, with its size modified from 120′ to 7.5′. All recordings were
performed twice, with 50 stimulations each. Sweeps were continued until the averaged potential
stabilized. Available equipment varied between study centers, so applied procedures could not be
strictly standardized, but a pattern size of 15′ was used in all centers. Electrograms were evaluated and
latencies and amplitudes of the P100 wave were recorded by two experienced neurologists. Only if
both investigators rated the electrogram as acceptable were data included in the database. As outcome
parameter P100, latency (ms) of the 15′ pattern size was defined a priori.
Raven’s Progressive Matrices (RPM) were used to assess cognitive performance. Depending on the
local availability for the corresponding age range, standard progressive matrices or colored progressive
matrices were applied [22]. Although not all children could be tested with identical procedures,
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care was taken to apply the same test pre and post intervention for each child and to ensure a similar
test environment. While this precluded a comparison between the centers, this procedure seemed
suitable for evaluating changes over time.
The fine and gross motor skills were tested with the Lincoln-Oseretzky Motor Development Scale
(LOS-SF 18). The LOS corresponds to the Motometric Rostock-Oseretzky Scale by Kurth, as described
in detail by Beblo et al. [13], but provides the advantage of commercially available standardized test
equipment. The sum of raw scores from 18 subtests (e.g., coin sorting, clapping, and walking on a
thin line) is converted to age-related standardized T-Scores (mean 50, SD = 10). The same investigator
examined the child at baseline and post-intervention in the same room. Parents could only attend
the investigation to support their children. Investigators from all centers participated in a videotaped
training session.
Medical treatments, physical examinations, and anthropometric measurements were determined
by the individual study centres. Caregiver reports of the children’s competencies and behavior
problems were obtained via the Child Behavior Checklist/ 4-18 (CBCL) [23].
2.4. Biochemical Measures
Non fasted venous blood samples were collected in plain and EDTA coated tubes and serum
and plasma were obtained according to study center routines. From the serum samples, cholesterol,
LDL cholesterol, HDL cholesterol, triacylglycerol, and Phe levels were determined at the centers by the
local clinical chemistry units. From the EDTA, blood plasma aliquots were used for the determination of
glycerophospholipid (GPL) fatty acids. The cell sediment was used for extracting DNA for genotyping
from the leucocytes. For these analyses, plasma and cell sediment samples were sent on dry ice to the
Dr. von Hauner Children’s Hospital, Munich and the Helmholtz-Zentrum, Munich, respectively.
Quantification of GPL fatty acids in plasma was performed as described before [24]. Selective
preparation of methyl ester derivatives of glycerophospholipid bound fatty acids was achieved
by co-precipitation of triacylglycerols and cholesterol esters with proteins and base catalysed
transesterification, excluding methyl ester synthesis from non-esterified fatty acids. Gas chromatographic
analysis using a 50 m long BPX70 column with a 0.22 mm inner diameter (SGE Europe, Milton Keynes,
UK) enabled the quantification of 29 fatty acids with a chain length from 14 to 22 carbon atoms, including
14 saturated or monounsaturated fatty acids; the polyunsaturated fatty acids of the n-6 series: C18:2cc,
C18:2tt, C18:3, C20:2, C20:3, C20:4, C22:4, and C22:5; from the n-3 series: C18:3, C18:4, C20:3, C20:5, C22:5,
and C22:6; and the n-9 polyunsaturated C20:3. The coefficients of variation observed for the analysis
varied from 1.8% to 30%, and for DHA, a coefficient of variation of 6.2% was obtained (n = 11).
2.5. Genotyping
The extraction of genomic DNA from the cell sediment was performed by a standard
salt-precipitation method. Genotyping was conducted using matrix-assisted laser desorption/ionization
time-of-flight mass spectrometry (MALDI-TOF MS) to detect allele-specific primer extension products
(Mass Array, Agena Bioscience, San Diego, CA, USA). Validated standard protocols according to Agena
Bioscience’s instructions were applied.
SNPs for genotyping in the FADS gene cluster and fatty acid elongase 5 were selected on the basis
of positional and functional aspects, as described before [16]. Genotyping data were analyzed with
Sequenom’s Typer Analyzer Software package.
2.6. Sample Size Estimation and Data Analysis
The number of patients recruited was planned to test a beneficial effect of at least 4 mg/kg&day
DHA intake by a paired comparison of VEP latencies pre and post intervention. Assuming an
intra-individual correlation of VEP latencies of 0.5 and considering the standard deviation of P100
latencies of 6.2 ms, as observed by Beblo et al. [14], a clinically relevant change of 4 ms could be
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expected to be detected as statistically significant with a probability of 80.3% (α = 0.05, two tailed test)
from repeated measurement of a sample of 21 subjects.
Thus, already with 21 subjects, the study would have been adequately powered to detect an effect
of a 4 mg/kg&day DHA intake, but as we aimed to identify a dose-response relationship between
DHA intake and the functional outcome VEP latency, we had to recruit more subjects and allocate
them to different doses of DHA intake to cover the range of intakes from 0 to 7 mg/kg&day for the
detection of potential dose-response relationships. We estimated that with 125 subjects with different
intakes per kg, including at least 21 subjects in a placebo group, we would be able to identify a linear
association between DHA intake and VEP latency.
Data were recorded on forms for later incorporation into an electronic database (Microsoft Excel).
In the database, the results of the laboratory analyses and the outcome of the neurological and cognitive
testing were also added. After the entry of all data and accuracy checking, the database was closed.
Thereafter, the dose allocation was unblinded.
2.7. Statistical Analyses
Results are presented as mean ± standard deviation. For comparisons between subgroups of
subjects, ANOVA or chi2-tests have been applied for continuous or categorical variables, respectively.
Correlations according to Pearson were used to describe associations. The influence of DHA intake
on the outcome parameters was tested by multiple linear regression analysis using the pre-study
values and the DHA intake as predictors and by paired t-tests comparing pre and post values stratified
according to DHA intake. Factors such as age, plasma Phe concentration, and genetic polymorphisms,
were tested by linear regression analysis for an influence on the outcome parameters. P-values of less
than 0.01 were considered as statistically significant, where appropriate p-values were adjusted for
multiple testing according to Bonferroni.
Statistical calculations were performed using the Software Package for Social Sciences (Version 22,
SPSS Inc. Chicago, IL, USA) and for testing for Hardy-Weinberg equilibrium and the calculation of
allele frequency, the Chi-sq Hardy-Weinberg equilibrium test calculator available online for biallelic
markers was applied [25].
3. Results
From Jan 2008 to July 2010, 114 subjects from six study centers were enrolled in the study
(Figure 1). After the pre study examination and biosample collection, 109 began the intervention
(Figure 1). Post-intervention assessments of VEPs and tests of cognitive function and motor skills
were completed by 95 children (Figure 1). Fourteen children terminated participation because parents
withdrew consent (n = 7), were lost to follow up (n = 3), or for unspecified reasons (n = 4). Some of the
performed tests did not meet the preset quality control criteria and were excluded from the evaluation,
which left 74 PKU children with a complete VEP15 dataset, 78 LOS datasets, and fully evaluable RPM
data in 80 children. Fatty acid analyses including pre and post intervention data could be evaluated
from 82 children. The evaluated children from the individual study centers are described in Table 1.
There were significant differences between the study centers with respect to fatty acid status and
baseline values of outcome tests, but analysis of variance did not reveal a significant effect of study
centers on the change of the parameters during the study (Supplementary Table S2).
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Figure 1. Participant flow chart according to CONSORT.
The percentage of subjects with usable data for the primary outcome differed significantly between
study centres (p = 0.003, chi2-test), from 44% to 93%. Mean arentally reporte numbers of consumed
capsules as an indicator of compliance with the study protocol ranged from 96% (Birmingham,
Santander) to 102% (Istanbul), with a mean of 98% of the number of capsules to be consumed,
without significant differences between the study centres (p = 0.08, ANOVA). No severe adverse side
effects and no vomiting due to capsule intake were reported. Three children reported nausea and six
children experienced fishy regurgitation. Occurrence of adverse events was not associated with higher
DHA intake.
Table 1. Baseline description of the evaluated study participants in the individual study centres, data
are given as mean ± SD or percentage.
Munich Birmingha t der il i l erg Istanbul
n 14 2 9
age (years) 8.0 ± 2.4 9.2 2.4 8.9 ± 2.9 10.6 3.3 8.5 2.1 9.3 ± 2.7
male (%) 71 59 33 67 44 67
mat. ed. & (%) # 14 36 8 11 40 0
weight (kg) 26.8 ± 8.2 35.2 ± 14.8 34.3 ± 15.8 34.9 ± 14.8 32.6 ± 10.8 31.6 ± 11.4
VEP15 (ms) * 119.0 ± 13.5 108.5 ± 7.3 110.1 5.5 110.5 ± 6.5 110.6 ± 5.8 115.3 4.1
RPM score * 111.4 ± 20.3 1 1 0 25.1 97.1 ± 22.0 123.3 ± 19.4 97.2 ± 22.0 85.6 ± 16.7
LOS T-score * 55.8 ± 7.5 49.3 ± 9.0 62.2 ± 10.1 58.8 ± 7.9 60.8 ± 9.0 57.7 ± 8.0
CBCL score 54.1 ± 12.2 48.6 ± 11.9 55.2 ± 9.1 51.2 ± 10.8 53.7 ± 9.9 47.1 ± 6.6
Phe (µmol/L) 230 ± 175 347 ± 201 303 ± 115 338 ± 268 323 ± 268 364 ± 113
TG (mmol/L) 1.29 ± 0.63 1.14 ± 0.68 0.77 ± 0.26 0.90 ± 0.30 1.17 ± 0.45 1.11 ± 0.41
CHOL (mmol/L) 3.52 ± 0.48 .47 .78 3.63 ± 0.57 3.70 0.52 3.78 0.55 3.40 ± 0.50
DHA * (% wt/wt) 2.36 ± 0.59 2.52 0.77 1.46 ± 0.42 1.85 0.34 2.87 1.01 1.36 ± 0.61
ARA (% wt/wt) 10.17 ± 2.00 10.04 ± 2.36 9.75 ± 2.39 10.30 ± 0.91 9.57 ± 1.68 11.48 ± 2.53
ALA * (% wt/wt) 0.35 ± 0.15 0.42 ± 0.23 0.15 ± 0.06 0.16 ± 0.08 0.37 ± 0.17 0.14 ± 0.10
LA * (% wt/wt) 22.62 ± 2.54 22.15 ± 3.20 21.45 ± 3.12 19.03 ± 2.21 21.37 ± 4.26 25.66 ± 3.76
# significant differences between study centers according to chi2-test; * significant differences between study centers
according to ANOVA; & percentage of mothers who completed school, qualifying for university.
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The effect of DHA dose on the outcome parameters was studied using multiple linear regression
considering the pre-values and DHA dosage per kg of body weight (Table 2). While functional
outcomes and fatty acid status after intervention were all strongly associated with the corresponding
pre study results, only DHA concentration and percentage values were significantly associated with
DHA intake. However, there were no significant relationships between DHA intake and functional
outcome parameters, although between 33% (plasma TG) and 64% (RPM) of the post intervention
variances were explained by the model (Table 2). The latency at pattern size 15′, latencies at other
pattern sizes, and amplitudes of the VEPs were not influenced by the intervention (Supplementary
Table S3). The influence of the DHA status on the neurological and cognitive outcomes was further
investigated by relating DHA levels at baseline and after intervention to these parameters, which did
not identify any significant relationship (Figure 2). Pre and post intervention VEP 15 latencies were
unrelated to Phe levels, but LOS and RPM scores showed a tendency to decrease with increasing Phe
levels (Figure 3). Nevertheless, in univariate analyses, maximally 6% of the variance in an outcome
parameter (pre value of RPM) was explained by the Phe levels.
A potential influence of DHA intake was also investigated by comparing changes after
stratification into supplementation groups with 0 mg DHA/kg&day, >0 mg DHA/kg&day but
<1.9 mg/kg&day, and ≥1.9 mg/kg&day (Table 3). The stratification into groups with no, lower,
and higher intakes did not show significant group differences between the changes, but a trend
towards a higher RPM increase in the zero-intake group. Only in the group with zero DHA intake
(placebo group) was the change of the LOS T-score significantly different from 0, while all other
changes were only minor and not significantly different from 0 (Table 3).
Table 2. Association between study DHA intake and pre intervention values with the post intervention
status of fatty acids and functional outcomes; outcomes were regressed on DHA intake and
corresponding pre study value, R2 corresponds to the percentage of outcome variance explained
by the regressors (DHA intake and pre value), significant associations (p < 0.01) are printed in bold.
n R2
Stand. β for
DHA Intake p
Stand. β for
Pre Value p
LOS T-score 78 40 −0.016 0.857 0.644 4.0 × 10−10
RPM-score 80 64 −0.108 0.118 0.808 5.0 × 10−19
VEP15 (ms) 74 57 −0.027 0.727 0.764 8.2 × 10−15
DHA-% 82 66 0.653 7.5 × 10−16 0.532 3.4 × 10−12
DHA (mg/L) 82 63 0.614 7.4 × 10−14 0.551 4.9 × 10−12
LDL/HDL 71 55 −0.055 0.495 0.749 7.4 × 10−14
Chol. (mmol/L) 76 38 0.109 0.239 0.602 7.5 × 10−9
TG (mmol/L) 79 33 0.049 0.601 0.59 1.3 × 10−8
LA (mg/L) 82 32 0.144 0.121 0.556 4.5 × 10−8
ALA (mg/L) 82 32 −0.006 0.948 0.577 2.4 × 10−8
ARA (mg/L) 82 29 −0.118 0.215 0.526 3.3 × 10−7
Table 3. Change of TG, Chol., LDL, HDL, VEP15, RPM-score, and LOS T-score during the
intervention period, stratified into three groups according to the daily dosage of DHA (0, >0 to
<1.9, ≥1.9 mg/kg&day); changes in the three groups were compared by ANOVA.
0 (n≥ 15) >0 to <1.9 (n≥ 15) ≥1.9 (n≥ 42) p-Value (ANOVA)
DHA (mg/L) 0.0 ± 9.1 5.1 ± 10.3 19.5 ± 13.6 1.3 × 10−8
TG (mmol/L) −0.1 ± 0.7 0.0 ± 0.5 0.1 ± 0.5 0.595
Chol. (mmol/L) −0.1 ± 0.6 0.0 ± 0.5 0.1 ± 0.5 0.795
LDL (mmol/L) −0.3 ± 1.2 0.2 ± 0.5 −0.1 ± 0.5 0.397
HDL (mmol/L) 0.0 ± 0.3 0.0 ± 0.3 0.0 ± 0.2 0.865
VEP15 (ms) 1.3 ± 3.5 0.5 ± 8.7 −0.6 ± 4.7 0.527
RPM-score 9.5 ± 13.5 2.2 ± 15.8 1.6 ± 13.8 0.016
LOS T-score 2.9 ± 7.0 4.2 ± 6.3 0.8 ± 9.1 0.371
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intervention period, stratified into three groups according to the daily dosage of DHA (0, >0 to <1.9, 
≥1.9 mg/kg&day); changes in the three groups were compared by ANOVA. 
 0 (n ≥ 15) >0 to <1.9 (n ≥ 15) ≥1.9 (n ≥ 42) p-Value (ANOVA) 
DHA (mg/L) 0.0 ± 9.1 5.1 ± 10.3 19.5 ± 13.6 1.3e−8 
TG (mmol/L) −0.1 ± 0.7 0.0 ± 0.5 0.1 ± 0.5 0.595 
Chol. (mmol/L) −0.1 ± 0.6 0.0 ± 0.5 0.1 ± 0.5 0.795 
LDL (mmol/L) −0.3 ± 1.2 0.2 ± 0.5 −0.1 ± 0.5 0.397 
HDL (mmol/L) 0.0 ± 0.3 0.0 ± 0.3 0.0 ± 0.2 0.865 
VEP15 (ms) 1.3 ± 3.5 0.5 ± 8.7 −0.6 ± 4.7 0.527 
RPM-score 9.5 ± 13.5 2.2 ± 15.8 1.6 ± 13.8 0.016 
LOS T-score 2.9 ± 7.0 4.2 ± 6.3 0.8 ± 9.1 0.371 
Figure 3. Association of the latency of visually evoked potentials with pattern size 15′ (VEP15 latency),
the Ravens score (RPM), and the Lincoln-Oseretzky score (LOS) with the plasma phenylalanine (Phe)
concentrations (µmol/L) before (pre) and after (post) intervention.
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A total of 22 SNPs previously related to ∆6 desaturation, ∆5 desaturation, or fatty acid acyl chain
elongation were considered in respect to their influence on ARA, DHA, VEP15 latency, RPM score,
and LOS T-score. After correction for multiple testing, only ARA levels were significantly influenced
by some SNPs based on linear regression analyses without considering potential confounding factors
(Table 4). Considering adjustment for multiple testing only for ARA levels, significant associations
with genotypes could be found and for none of the tested SNPs was a significant association with
DHA or functional outcomes found.
DHA intake was linearly related to absolute DHA concentrations and DHA-% in plasma GPLs
over the whole tested dose range (Figure 4). Multiple regression analysis was used to investigate
the influence of the rs174548 genotype, corresponding essential precursor fatty acid concentrations,
total concentration of determined GPL bound saturated fatty acids, and DHA intake on the major n-3
and n-6 LC-PUFA. Saturated fatty acids, but not monounsaturated fatty acids, were included in the
model to account for the possibility that LC-PUFA incorporation into GPLs could be influenced by the
availability of saturated fatty acids to be combined with essential fatty acids or LC-PUFA in plasma
GPL. The models were set up for the pre- and post-intervention data (Table 5). For all considered fatty
acids, significant models were identified. The variance explained by these factors ranged from 36% for
n-6 docosapentaenoic acid (DPA) to 84% for EPA in the pre-intervention data and from 43% for ARA to
90% for EPA in the post-intervention data. Post-intervention DHA intake was significantly positively
related to DHA levels and significantly negatively related to ARA and n-6 DPA. Post-intervention,
the different DHA intakes during the study period (0 mg/kg&day to 7 mg/kg&day) were the major
determinants of DHA levels. ALA levels showed the highest β in the pre-intervention situation
and were found to be related to DHA concentration. The Rs174548 genotype was related to most
LC-PUFA concentrations, and significant interactions between genotype and essential precursor fatty
acid concentrations were seen for EPA, n-3 DPA, DGLA (pre only), and DHA (pre only). Interestingly,
ARA was only related to the genotype and not to the LA concentration (Figure 5a), while in the case of
DHA, the ALA precursor level and genotype were both significantly related to DHA (Figure 5b).
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Table 4. SNPs considered in the genetic analyses and significance of their influence on pre study ARA-%, DHA-%, VEP latency, LOS T-score, RPM score, and change
of DHA and VEP latency; statistically significant effects (p < 0.00045, considering Bonferroni adjustment are printed in bold, n = 82).
dbSNP Major/Minor Gene HWE a MAF b %-ARA pre
DHA-%
pre
VEP Latency
pre LOS pre RPM pre
VEP
Latency
Change
DHA-%
Change
rs174579 C/T FADS2 0.01 0.19 4.0× 10−4 >0.1 >0.1 >0.1 >0.1 >0.1 8.0 × 10−3
rs174449 A/G FADS3 0.56 0.43 5.4 × 10−2 3.0 ×−3 >0.1 >0.1 >0.1 >0.1 >0.1
rs968567 C/T FADS2 0.33 0.13 2.0 × 10−3 >0.1 >0.1 >0.1 >0.1 >0.1 6.6 × 10−2
rs526126 C/G FADS2 0.95 0.19 2.7 × 10−2 >0.1 >0.1 >0.1 >0.1 >0.1 >0.1
rs174455 G/A FADS3 1.18 0.46 7.0 × 10−2 2.4 × 10−2 >0.1 >0.1 >0.1 >0.1 >0.1
rs498793 C/T FADS2 0.71 0.35 >0.1 >0.1 >0.1 >0.1 >0.1 >0.1 >0.1
rs174570 C/T FADS2 0.33 0.13 1.1 × 10−2 >0.1 >0.1 >0.1 >0.1 >0.1 >0.1
rs174561 T/C FADS 3.04 0.28 7.6× 10−9 3.4 × 10−2 >0.1 >0.1 >0.1 >0.1 9.9 × 10−2
rs3834458 T/del FADS2 2.47 0.30 1.3× 10−7 3.6 × 10−2 >0.1 >0.1 >0.1 >0.1 8.9 × 10−2
rs174548 C/G FADS1 1.86 0.29 7.2× 10−10 1.5 × 10−2 >0.1 >0.1 >0.1 >0.1 >0.1
rs174575 C/G FADS2 0.01 0.25 1.0× 10−5 2.5 × 10−2 >0.1 >0.1 >0.1 >0.1 2.0 × 10−2
rs174627 G/A FADS2 0.08 0.13 >0.1 >0.1 >0.1 >0.1 >0.1 >0.1 >0.1
rs174602 T/C FADS2 0.06 0.24 1.5 × 10−2 3.0 × 10−3 >0.1 >0.1 >0.1 >0.1 >0.1
rs174464 G/A FADS3 0.79 0.38 4.0 × 10−3 7.0 × 10−3 >0.1 >0.1 >0.1 >0.1 >0.1
rs174468 T/C FADS 8.37 c 0.27
rs17544159 A/C ELOVL 0.54 0.08 >0.1 9.7 × 10−2 2.5 × 10−2 >0.1 >0.1 4.3 × 10−2 >0.1
rs12207094 A/T ELOVL5 1.69 0.13 >0.1 >0.1 >0.1 >0.1 >0.1 >0.1 3.0 × 10−2
rs2397142 C/G ELOVL5 0.94 0.29 >0.1 >0.1 >0.1 >0.1 >0.1 >0.1 >0.1
rs209515 G/A ELOVL5 0.05 0.38 >0.1 >0.1 >0.1 >0.1 >0.1 >0.1 1.4 × 10−2
rs715441 T/C ELOVL5 0.18 0.14 >0.1 1.9 × 10−2 >0.1 >0.1 >0.1 >0.1 >0.1
rs209512 T/C ELOVL5 4.31 c 0.19
rs735860 T/C ELOVL5 0.01 0.44 >0.1 >0.1 >0.1 >0.1 >0.1 >0.1 >0.1
a chi2 of Hardy-Weinberg (HWE) test performed according to [25], critical value 3.86 (p = 0.05) b MAF: minor allele frequency c not in HWE equilibrium and not further considered.
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Table 5. Pre and post study associations between essential fatty acid concentrations (LA, ALA), rs174548 genotype, total saturated fatty acid concentration and DHA
intake (post intervention only), and major n-3 and n-6 long chain polyunsaturated fatty acid concentrations; only significant (p < 0.01) standardized β-coefficients are
given (n = 82).
R2
β DHA
Intake p-Value β LA p-Value β ALA p-Value
β
rs174548 p-Value
β Total
Saturated
Fatty Acids
p-Value
β rs174548
×
Precursor
p-Value
pre
DGLA 0.69 −0.22 4.1 × 10−3 0.30 1.0 × 10−6 0.86 1.1 × 10−18 −0.17 4.0 × 10−3
ARA 0.57 −0.44 3.3 × 10−9 0.53 1.1 × 10−7
DPA n-6 0.36 −0.51 2.5 × 10−7 0.66 7.2 × 10−8
EPA 0.84 −0.33 7.6 × 10−9 0.83 3.5 × 10−30 −0.18 2.3 × 10−5 0.44 4.8 × 10−12 −0.28 7.8 × 10−9
DPA n-3 0.69 −0.21 5.6 × 10−3 0.61 5.2 × 10−14 −0.24 7.8 × 10−5 0.59 1.8 × 10−9 −0.18 5.3 × 10−3
DHA 0.60 0.65 9.5 × 10−13 −0.28 4.9 × 10−5 0.36 1.2 × 10−4 −0.23 1.4 × 10−3
post
DGLA 0.61 −0.23 8.5 × 10−3 −0.21 3.9 × 10−3 0.44 3.6 × 10−8 0.87 1.6 × 10−17
ARA 0.43 −0.39 2.7 × 10−5 0.52 1.0 × 10−6
DPA n-6 0.47 −0.39 3.9 × 10−6 −0.52 1.7 × 10−8 0.68 1.9 × 10−10
EPA 0.90 −0.20 4.8 × 10−6 0.80 1.0 × 10−36 −0.20 3.2 × 10−7 0.27 3.3 × 10−8 −0.18 6.7 × 10−7
DPA n-3 0.69 0.55 7.0 × 10−13 −0.21 1.7 × 10−3 0.41 2.4 × 10−7 −0.16 9.5 × 10−3
DHA 0.51 0.54 2.3 × 10−10 0.30 4.0 × 10−4 0.30 1.3 × 10−3
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4. Discussion
Dietary intake of DHA led to a proportional increase of DHA in plasma GPLs, but a beneficial
effect of improved DHA status on the tested cognitive and neurological functions in children with
PKU was not seen with the dosage range tested. The study confirmed the high importance of the
FADS genotype for the LC-PUFA status. It also demonstrated that in the absence of an exogenous
supply of LC-PUFA, the availability of the precursor fatty acid ALA modulates DHA status.
The lack of significant improvement of neurological and cognitive function in the PKU children is
in line with observations in healthy children and adolescents, which often do not report a significant
benefit of DHA or fish oil supplementation [26]. Our intervention can be compared with n-3
supplementations in healthy children, which have typically applied dosages from 100 to 1200 mg
per day [27–32] and even higher doses in studies with patients suffering from various disorders [33].
This corresponds to dosages of around 20 mg/kg; thus, our applied dosage of maximally 7.5 mg/kg
was comparatively low, even though we used pure DHA and not a mixture of DHA and EPA. As the
majority of the participating children received DHA dosages clearly below 250 mg per day, our findings
are in line with the EFSA scientific opinion that the dietary DHA intake of children from 2 to 18 years
should be 250 mg [34]. Thus, based on our data, an optimal intake cannot be defined.
Beblo et al. reported, after supplementing PKU children for three months with more than
15 mg/kg&day, DHA percentages of DHA in plasma phospholipids of 7.1± 0.1% (M± SEM), while we
saw maximal values of around 5.5% [13]. The initial DHA percentages in our study participants showed
considerable differences between the study centres, with very low values in some centres, whereas
in Munich, Heidelberg, and Birmingham, DHA values were only slightly lower than the mean 2.9%
DHA found in healthy omnivorous German children [35]. In contrast, average ARA values for all
study centres were higher than those observed in healthy children, confirming previous observations
that PKU children present with low DHA, but with normal or high ARA values [4,36]. The essential
fatty acid LA was similar to the healthy children in most study centres, but in Milan, values were low
and Istanbul, they were high (25%). For ALA, there were two different trends among study centres,
with mean values <0.2% in Istanbul, Santander, and Milan, and mean values >0.3% in both German
centres and in Birmingham. The German cohort of healthy children had 0.22% (0.10) [median (IQR)]
ALA in their GPL fatty acids [35], which indicates that ALA supply was good in some centres, but
low in others, presumably reflecting the use of different vegetable oils in the diet. Our data confirm
previous findings that PKU patients show lower n-3 LC-PUFA than healthy controls, but the differences
between healthy omnivorous children and the PKU patients were small in some centres. The DHA data
from Istanbul, Santander, and Milan confirm the findings of the 2013 Lohner review [7], while German
and UK sites support recent observations from a German PKU study that there was no significant
difference between patients and controls [37].
Animal studies and several studies in humans indicate beneficial effects of DHA on measures
of cognitive and neurological functions [38], and this might also apply to PKU patients, who very
early on, develop low DHA levels without an intake of DHA [39]. As no fully standardised reference
method was applied and as we did not include a healthy reference group, we cannot demonstrate
that the observed latencies of the VEPs were longer than in healthy controls, but this is suggested by
a comparison with the findings of Beblo and Agostoni, who found similar latencies in PKU patients
which differed from healthy controls [14,15]. For the IQ testing, there is a broad variance of the
results, but we did not observe mean test results below the expected norm. The LOS test for motor
skills yielded results which tended to be above average, providing no indications of deficits in PKU
children [40], as reported previously [13]. The CBCL scores did not give reasons to exclude a participant,
but otherwise, we did not further consider this parameter in the evaluations. As for other parameters,
there were clear differences between the centres. Additionally, the study participants had no clinically
relevant abnormalities of triglyceride and cholesterol levels, which did not significantly change during
the intervention period.
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The statistical evaluation did not reveal significant improvements of any of the tested neurological
and cognitive functions, but rather a considerable stability of the test results. While DHA intake was
not significantly associated with post intervention LOS T-scores, VEP latencies, or IQ, between 40%
and 64% of the post intervention variance was explained by the pre value. In an alternative evaluation,
a comparison of the change of the neurological outcomes of the children with DHA intakes of at
least 1.9 mg/kg to those without DHA intake did not indicate any significantly greater improvement
in supplemented children. Thus, the data indicate reproducible and valid measurements, but no
systematic benefit from the DHA supplementation.
It was previously shown that infants with the FADS genotype associated with less endogenous
production of LC-PUFA particularly benefit from the provision of exogenous DHA [41], so we
took genotype into account in our evaluations, but this did not change the findings. Similarly,
analyses stratified according to the study centres (data not shown) did not indicate an effect of
DHA supplementation. A further indication that in the range studied, DHA status and intake do not
influence neurological and cognitive outcomes, is that neither basal nor post intervention significant
associations between GPL DHA and the outcomes could be found. According to observations in
non-human primates [42], six months of supplementation should allow for brain DHA to adapt to
supplementation and leave time to improve cognitive function.
In agreement with the observations in the general population, DHA levels were clearly affected
by DHA supply [43]. The observed proportionality of the dosage of DHA supply with the percentage
increase in blood lipids confirms observations in adults and pregnant women given higher doses of
DHA+EPA [44,45]. Considering the influence of body weight on the DHA concentration changes
observed after supplementation [46] and the range of body weights in children aged 5 to 13 years,
we related DHA change to DHA intake per kg body weight and found a linear relationship over the
full tested range up to 7 mg/kg. This is in agreement with an observation in adults who consumed
fish oil (EPA/DHA = 6/4) for five months and showed a linear association between intake and red
blood cell omega-3 index up to a daily intake of 1800 mg, corresponding to 30 mg/kg [47].
In adult studies, the increase of the DHA status as % or concentration was not only dependent
on the intake, but also on the baseline level, with a negative association between baseline and
increase [44,47]. In our data, baseline DHA and daily intake had a similar influence on the
post-supplementation DHA and together, these factors explained about two thirds of plasma GPL DHA
variance. Although the change of DHA was inversely associated with the baseline level, the pre-value
and the dose were both positively associated with the post-value. Thus, we can assume that there are
two different sources of DHA which define the post-value, i.e., the study related supplement intake
and the endogenous synthesis. It has been shown that FADS expression in the liver is attenuated by
DHA [48], thus more reduction of endogenous synthesis can be expected from participants with high
initial DHA levels driven by endogenous synthesis, as observed here. Furthermore, in the absence
of dietary DHA, as given at the baseline, it can be expected that the endogenous DHA production is
highest, indicating that the DHA levels are achievable without exogenous supply.
Previous studies in humans with stable isotopes have found variable, but generally low,
conversion rates of ALA to DHA [49,50], which seem insufficient to provide an optimal brain DHA
content. This is supported by the finding that ALA supplementation does not lead to a significant
increase of DHA levels in most studies [49]. Since DHA levels are associated with fish or supplement
intake [51], it is evident that optimal DHA levels depend on DHA intake [52]. Nevertheless, recent
studies in mice have suggested that endogenous synthesis from ALA provided by a 2% ALA (weight-%
of dietary fat) diet can only establish an 8% lower brain DHA content compared to a diet containing
1.8% preformed DHA [53].
Nevertheless, to some degree, low LA combined with high ALA intake can increase DHA levels
in humans [54]. A constant infusion of non-esterified labelled ALA showed that the conversion rate of
ALA to DHA was the same in mice fed 3% ALA of all dietary fatty acids as in mice fed a diet with
only 0.1% ALA. Interestingly, in mice fed a 10% ALA diet, the conversion rate decreased and DHA
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levels were the same as with the 3% diet [55]. Endogenous DHA synthesis is considered to be lower
in humans than in mice [56], but it seems to contribute to DHA status. Although the efficacy of the
direct intake of preformed DHA is much stronger, endogenous ALA conversion seems to be relevant,
particularly if the DHA intake is very low, as in non-supplemented PKU patients. The importance of
ALA as a source for DHA was reported for PKU patients who showed a significant increase of their
DHA levels after an increase of the ALA intake relative to the LA intake [57].
In our study, the multiple regression analyses indicated that DHA levels were significantly
associated with ALA levels in the absence of DHA intake, and also with a DHA intake up to 7 mg/kg
body weight per day. A relevant endogenous DHA synthesis is also indicated by the influence
of the FADS genotype on DHA levels, if considered jointly with the precursor level. For n-6 fatty
acids, the level of the precursor LA is barely related to the level of the conversion product ARA,
while genotype is of significant importance [19,58]. This indicates that it is not the precursor, but
the enzymatic conversion capacity, which primarily limits ARA levels, which contrasts to the n-3
side. Interestingly. in our model, which took the already previously observed correlation among
all phospholipid bound fatty acids [59] into account by including total saturated fatty acids as a
predictor, LA levels did not negatively affect DHA levels, although EPA was negatively affected.
In agreement with previous observations [60] and the assumed importance of ALA for endogenous
DHA synthesis, DPA-n6 was the fatty acid most strongly negatively affected by DHA intake and
the ALA level. With the applied model, 84% and 90% of the variance of EPA concentrations were
explained pre-intervention and post-intervention, respectively. The similarity of the coefficients of
determination pre- and post-intervention suggests the absence of a significant association between
DHA intake and EPA levels and does not support a quantitatively relevant retroconversion of DHA to
EPA [61]. For some LC-PUFA, significant negative interactions between precursor level and genotype
were seen, with the strongest effects for EPA. This could reflect that at higher ALA levels, delta 5
desaturation encoded by FADS (rs174548) could become limiting, and the precursor ALA and the
conversion products compete for incorporation into the phospholipids.
The GPL DHA percentage increased linearly with DHA intakes by 0.4% per 1 mg/kg&day from
2.4% to 5%. Without accountable DHA intake, the average DHA-% was 2.4%, which would correspond
to an endogenous synthesis of 6 mg DHA per kg&day (6 times 0.4%), if extrapolation from the intake
derived estimate would be valid. However, it has been found in elderly adults that DHA turnover
decreases with lower intake [62], so it can be assumed that a DHA production of 6 mg/kg&day from
ALA overestimates the real production. Nevertheless, the quantitative importance of ALA desaturation
and elongation is obvious from the large portion of the variation in basal DHA that can be explained
by the ALA levels and the FADS genotype. Considering daily ALA intakes of about 20 to 40 mg/kg in
children and adolescents [63,64] and conversion of a dietary ALA to DHA up to 9% in humans [65]
and even higher in mice [66], it is conceivable that in the PKU patients, a diet high in ALA can establish
significant DHA levels in situations with low requirement due to low turnover. As the expression of
desaturases is decreased by higher DHA levels [48], a higher DHA intake may induce lower conversion
rates, explaining that in tracer studies, very low conversion rates have often been found [66].
The situation in the PKU patients without relevant DHA intake provided a unique opportunity to
study LC-PUFA metabolism and the influence of DHA on cognitive function, and we obtained highly
significant results, although less than the planned number of subjects could be studied, but there
are some limitations. A known major determinant of cognitive function in PKU patients is the Phe
level, which could not be strictly controlled during the study and may influence the test results [67].
However, statistically controlling for the Phe levels did not change the findings, so we assume that this
did not obscure any association between DHA and the cognitive test results. Additional variance was
introduced due to the multicentric design of the study, which was associated with slight differences
of the test procedures between the centres. This precluded comparisons between the study centres
but should not have affected the examination of the change over time, which was adjusted for pre
study values. It might be criticized that the variance of essential fatty acid levels was mainly caused
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by differences between study centres, thus further factors, e.g., diets of the PKU patients, could have
been different between the centres, which would require inclusion of the study centre as a confounder
into the analysis. As this would no longer have allowed a meaningful examination of the associations
between the fatty acids and the effects of the dietary differences were considered via the GPL fatty acid
concentrations as biomarkers for fatty acid intake, this did not seem mandatory. With the availability
of valid dietary intake data for the essential fatty acids, it would have been possible to establish a
quantitative relationship between ALA intake and ALA plasma levels, LA intake and LA plasma
levels, and how these intakes influence DHA levels. With the available information, we can describe
the relationship between DHA intake and DHA levels, but we cannot compare the relative importance
of ALA and DHA intake for the DHA levels.
5. Conclusions
In conclusion, our results indicate that DHA intakes of up to 7 mg/kg&day in PKU children
lead to a linear increase of the DHA status, but not to any significant improvement of neurological or
cognitive functions. Neither pre- nor post-supplementation GPL DHA was significantly associated
with the tested neurological or cognitive functions. It is possible that larger dosages of DHA and
higher plasma and tissue levels might be required for significant improvements. In the absence of
dietary DHA, ALA supply and desaturase genotype have a significant influence on EPA and DHA
levels. Although endogenous synthesis might contribute low but biologically relevant DHA levels,
DHA intake should be at least 250 mg/day to obtain adequate levels in children.
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